Trial Profile
A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2020
Price :
$35
*
At a glance
- Drugs Darigabat (Primary) ; Lorazepam
- Indications Reflex epilepsy
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Apr 2019 Results presented in a Cerevel Therapeutics Media Release.
- 15 Mar 2019 Results published in the Neurology
- 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society.